- Psychedelic Journal Watch
- Posts
- Psychedelic Journal Watch
Psychedelic Journal Watch
Keeping health professionals abreast of the latest research in psychedelic medicine
I. Micro-dosing LSD for ADHD
Repetitive low-dose LSD is not effective for ADHD, according to JAMA Psychiatry.
In this double-blind, placebo-controlled, phase 2a randomized controlled trial, 53 individuals with moderate to severe ADHD received either LSD (20 μg) or placebo twice weekly for 6 weeks. ADHD symptoms were measured at baseline and at 6 weeks.
No significant difference was found between individuals receiving LSD compared to placebo, with both groups reporting an improvement in ADHD symptoms after 6 weeks.
According to the authors, “to our knowledge, this is the first double-blind, placebo-controlled randomized clinical trial to investigate effects of repeated low-dose (20 μg) LSD administration in adults with ADHD … Generally, LSD did not improve ADHD symptoms over placebo on any of the measures.”
II. Do SSRIs Affect Psilocybin-Assisted Therapy Outcomes?
Being on an SSRI antidepressant prior to starting psilocybin-assisted therapy (PAT) does not diminish the beneficial effects of PAT, according to The Canadian Journal of Psychiatry.
In this open-label, randomized controlled trial, involving 27 participants who received PAT, unmedicated individuals were compared to individuals who tapered off their SSRI antidepressant prior to starting PAT.
No significant differences were found in depression, anxiety, or suicidality outcomes, with both groups demonstrating clinically significant benefits.
According to the authors, “these findings contrast with and contribute to the growing literature on the effects of medication tapering leading up to psilocybin-assisted psychotherapy.”
III. Psilocybin-Assisted Therapy for Relapse Prevention in People with Alcohol Use Disorder
Psilocybin-assisted therapy does not prevent relapse or reduce alcohol intake, according to The Lancet.
In this double-blind, randomized clinical trial involving 37 participants, individuals received either one dose of psilocybin or placebo combined with psychotherapy; abstinence and mean alcohol use were measured at 4-weeks and 6-month follow-up.
There were no significant differences between the two groups in abstinence rates or mean alcohol use per day at 4-week and 6-month follow-up.
According to the authors, “a single dose of psilocybin combined with five psychotherapy sessions may not be sufficient to reduce relapse rates and alcohol use in severely affected AUD patients following withdrawal treatment. However, given the limited sample size of our study, larger trials are needed in the future to confirm these findings.”
Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms.
If you enjoy our newsletter, please forward it to your friends!
This newsletter is curated and published by:
Haven’t subscribed yet? Subscribe now!
Reply